Digital health is a broad concept that encompasses telemedicine, teleconsultation, remote monitoring, connected devices, digital health platforms and health applications. The outbreak of COVID-19 pandemic has propelled the usage of digital technologies in order to receive healthcare, remotely. The revolutionary developments in digital health have transformed medicine and biomedical science as well as promoted early disease diagnosis and treatment. In addition, several FemTech startups are focused on the development of products or offering services to women of all age groups dealing with issues related to pregnancy, periods and menopause. Owing to the increased adoption rate of digital solutions and rise in the demand for remote healthcare services, the companies involved in the women’s digital health domain have witnessed a surge in the investment activity, with capital investments worth more than USD 3 billion over the past few years. This has enabled the overall FemTech business to flourish. It is worth noting that, NC° Birth Control, developed by Natural Cycles, was the first application to receive approval from US FDA in 2018 and is CE marked in Europe. This application can be used as a method of contraception and to track menstrual cycles, regularly. Subsequently, in 2021, various other women’s digital health solutions received US FDA approvals, including Ava Fertility Tracker (first approved fertility tracking wearable) and Clue (period tracking and birth control app).
Currently, more than 200 women’s digital health solutions, including applications / software, wearable devices, and services have been marketed / are under development with applications across various therapeutic areas including, reproductive health / fertility, menstrual cycle, general wellness, pelvic care and fetal health. These digital health solutions provide motivational support and inculcate healthy lifestyle changes in the target patient population. In addition, by advocating more personalized and meaningful treatment for women, employers may advance health equity and aid in the eradication of healthcare inequities. Given the increasing research efforts and active involvement of investors, we anticipate the development of a variety of applications and devices focused on improving women’s health, in the coming years. Further, taking into consideration both the historical and contemporary scenarios, we believe that the women’s digital health market presents lucrative investment opportunities for both short and long term investors.
Scope of the Report
The Investor Series: Opportunities in Women’s Digital Health Market (Focus on Innovator Landscape, Analysis of Product Offerings and Company Health Indexing, Value Proposition Analysis, Company Competitiveness Analysis, Insights from Historical Funding and Investment Activity, Financial Analysis of Key Public Ventures, Market Forecast and Opportunity Analysis, Key Acquisition Targets, Business Risk Assessment and Return on Investments) report provides detailed information on the women’s digital health market, covering the core and peripheral women’s digital health solutions. It offers a technical and financial perspective on how the opportunity in this domain is likely to evolve, in terms of future business success, over the coming decade. The information in this report has been presented across multiple deliverables, featuring MS Excel sheets (some of which include interactive elements) and a MS PowerPoint deck, which summarizes the key takeaways from the project and insights drawn from the curated data. Amongst other elements, the report includes:
- An introduction to women’s digital health, highlighting some of the key application areas of the FemTech industry. It features various types of women’s digital health products / solutions that have either been marketed / are under development. In addition, the report highlights prominent barriers to the development and success of women’s digital health solutions, and the opinions of representatives from key stakeholder companies involved in this domain.
- A detailed analysis of women’s digital health focused companies that were established post-2006, featuring key insights on the observed trends related to the basic company parameters, such as year of establishment, location of headquarters, company size, and type of venture.
- An assessment of the various products / solutions, offered by the innovator companies, featuring analysis based on number and types of products. Based on the aforementioned insights, we have developed a quantitative perspective on the relative health (based on the company details, product portfolio, financing activity, estimated revenues and profits) of the different innovator companies that have been described in detail in this report. This analysis is based on a proprietary scoring criterion, informed via secondary research.
- An informed perspective on the value proposition of the companies captured in the report based on multiple relevant aspects, namely product-related value, value to patients, developer value and outreach-related value.
- A company competitiveness analysis, which offers a quantitative basis for comparing the strengths / contributions of various industry stakeholders that are involved in providing women’s digital health solutions. It is worth mentioning that this analysis is based on the insights generated from the abovementioned relative health indexing and value proposition analysis.
- A detailed analysis of the funding and investment activity that has taken place in this domain, since 2011. It also includes category-wise financing trends, describing the relative maturity (in terms of number of funding instances and total capital raised) of the innovator companies mentioned in the report. Further, it features a list of the leading investors in women’s digital health, based on their participation in financing activity in this industry segment.
- An elaborate review of the overall women’s digital health market from a financial perspective, including detailed fundamental (insights from the balance sheet and key financial ratios) and technical analysis (insights from historical and recent stock price variations as well as analysis using popular stock performance indicators) of financial data of the publicly listed companies within the innovators landscape dataset.
- A key acquisition targets analysis, based on the insights generated during the course of this study, highlighting some of the promising early-to-mid stage business ventures that are likely to be acquired / merged.
- A case study on the assessment of business risks, based on some of the major risk categories that are usually discussed in the industry, namely operations-related risks, business-related risks, financial / asset-related risks, product / technology risks, and others (social, economic, environmental and political risks).
- A case study where investors have exited various women’s digital health-related ventures, offering insights on return on investments received (based on availability of data). Leveraging the abovementioned details, the report offers an informed opinion on the future outlook for investors in the women’s digital health market.
One of the key objectives of the report was to identify the primary growth drivers and estimate the future growth opportunity associated with the women’s digital health market, over the coming decades. We have provided informed estimates on the likely evolution of the market in the short to mid-term and long term, for the period 2023-2035. Our year-wise projections of the current and future opportunity within the women’s digital health market have further been segmented across type of solution (applications / software, devices and services), therapeutic application area (fetal health, general wellness, menstrual cycle, pelvic care and reproductive health / fertility), and geography (North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America). In order to account for future uncertainties in the market and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Table of Contents
EXCEL DELIVERABLE
1. INNOVATORS AND PRODUCTS DATASET
1.1. Analysis Notes
1.2. Innovator Landscape
1.3. Product Landscape
1.4. Value Proposition
1.5. Key Acquisition Targets
1.6. AI - AVII Appendices
2. FUNDING AND INVESTMENT ANALYSIS
2.1. Analysis Notes
2.2. Summary Dashboard
2.3. Capital Investments in Women’s Digital Health
2.4 AI - AIV Appendices
3. FUNDAMENTAL AND TECHNICAL FINANCIAL ANALYSIS
The information presented in this analysis is spread across separate MS Excel sheets, which provide information on key financial parameters and competitive insights based on historical and prevalent trends.
4. MARKET FORECAST AND OPPORTUNITY ANALYSIS
4.1. Analysis Notes
4.2. Market Forecast and Opportunity Analysis: Marketed Products Dataset
4.3. Market Forecast and Opportunity Analysis: Pricing Dataset
4.4. Market Forecast and Opportunity Analysis: Summary
4.5. Market Forecast and Opportunity Analysis: Applications / Software (Base Scenario)
4.6. Market Forecast and Opportunity Analysis: Applications / Software (Conservative Scenario)
4.7. Market Forecast and Opportunity Analysis: Applications / Software (Optimistic Scenario)
4.8. Market Forecast and Opportunity Analysis: Devices (Base Scenario)
4.9. Market Forecast and Opportunity Analysis: Devices (Conservative Scenario)
4.10. Market Forecast and Opportunity Analysis: Devices (Optimistic Scenario)
4.11. Market Forecast and Opportunity Analysis: Services (Base Scenario)
4.12. Market Forecast and Opportunity Analysis: Services (Conservative Scenario)
4.13. Market Forecast and Opportunity Analysis: Services (Optimistic Scenario)
4.14. Market Forecast and Opportunity Analysis: Prevalence
4.15. Market Forecast and Opportunity Analysis: Validation
4.16. Market Forecast and Opportunity Analysis: Population Data
4.17. Market Forecast and Opportunity Analysis: UN World Population Data
5. RETURN ON INVESTMENTS
5.1. Analysis Notes
5.2. Estimated RoI for Investors in Company A
POWERPOINT DELIVERABLE
1. CONTEXT
2. PROJECT OBJECTIVES
3. PROJECT APPROACH
4. EXECUTIVE SUMMARY
Section I: Introduction to Women’s Digital Health Solutions and Innovators Landscape
5. THE WOMEN’S DIGITAL HEALTH MARKET
5.1. Overview
5.2. Importance of FemTech Industry
5.3. Digital Solutions focused on Women’s Health
5.4. Leading Products and Challenges
5.5. Case Study: Business Success and Decline
6. WOMEN’S DIGITAL HEALTH: INNOVATOR LANDSCAPE
6.1. Methodology
6.2. Innovators in the Women’s Digital Health Market
6.3. Analysis of Innovator Landscape
6.4. Concluding Remarks
7. WOMEN’S DIGITAL HEALTH: PRODUCT LANDSCAPE AND COMPANY HEALTH INDEXING
7.1. List of Products
7.2. Analysis of Product Landscape
7.3. Company Health Indexing Methodology
7.4. Company Health Indexing Scoring
7.5. Company Health Indexing
8. VALUE PROPOSITION ANALYSIS
8.1. Overview and Methodology
8.2. Product-related Value
8.3. Value to Patients
8.4. Developer Value
8.5. Outreach-related Value
8.6. Concluding Remarks
9. COMPANY COMPETITIVENESS ANALYSIS
9.1. Overview and Methodology
9.2. Company Competitiveness Analysis
Section II: Analysis of Investments
10. FUNDING AND INVESTMENT ANALYSIS
10.1. Overview
10.2. Analysis by Type of Funding
10.3. Analysis by Geography
10.4. Most Active Players and Popular Investors
10.5. Trends Across Various Funding Categories
10.6. Summary of Funding and Investments
Section III: Financial Analysis of Key Public Ventures
11. FINANCIAL ANALYSIS OF PUBLIC VENTURES
11.1. Fundamental Financial Analysis Overview
11.1.1. Financial Ratios (Interpretation Guide): Liquidity Ratios
11.1.2. Financial Ratios (Interpretation Guide): Financial and Business Risk Ratios
11.1.3. Financial Ratios (Interpretation Guide): Turnover / Efficiency Ratios
11.1.4. Financial Ratios (Interpretation Guide): Profitability Ratios
11.1.5. Financial Ratios (Interpretation Guide): Market Value Ratios
11.1.6. Financial Ratios (Interpretation Guide): Stability Ratios
11.1.7. Case Study 1
11.1.8. Case Study 2
11.1.9. Case Study 3
11.2. Technical Financial Analysis Overview
11.2.1. Technical Indicators (Interpretation Guide): Candlestick Charts
11.2.2. Technical Indicators (Interpretation Guide): Moving Averages
11.2.3. Technical Indicators (Interpretation Guide): Bollinger Band®
11.2.4. Technical Indicators (Interpretation Guide): Relative Strength Index
11.2.5. Technical Indicators (Interpretation Guide): William’s R Analysis
11.2.6. Technical Indicators (Interpretation Guide): Moving Average Convergence Divergence
11.2.7. Case Study 1
11.2.8. Case Study 2
11.2.9. Case Study 3
12. COMPANY PROFILES OF PUBLIC VENTURES
12.1. Bonzun
12.1.1. Key Highlights
12.1.1.1. Company Overview
12.1.1.2. Key Executives
12.1.1.3. Insights from Balance Sheet
12.1.1.4. Product / Service Portfolio
12.1.1.5. Recent Developments
12.1.2. Key Financial Details
12.1.2.1. Company Investments
12.1.2.2. Company Fundamentals
12.1.2.3. Company Technicals
12.2. HeraMED
12.2.1. Key Highlights
12.2.1.1. Company Overview
12.2.1.2. Key Executives
12.2.1.3. Insights from Balance Sheet
12.2.1.4. Product / Service Portfolio
12.2.1.5. Recent Developments
12.2.2. Key Financial Details
12.2.2.1. Company Investments
12.2.2.2. Company Fundamentals
12.2.2.3. Company Technicals
12.3. Sera Prognostics
12.3.1. Key Highlights
12.3.1.1. Company Overview
12.3.1.2. Key Executives
12.3.1.3. Insights from Balance Sheet
12.3.1.4. Product / Service Portfolio
12.3.1.5. Recent Developments
12.3.2. Key Financial Details
12.3.2.1. Company Investments
12.3.2.2. Company Fundamentals
12.3.2.3. Company Technicals
Section IV: Market Forecast and Opportunity Analysis
13. MARKET FORECAST AND OPPORTUNITY ANALYSIS
13.1. Overview and Methodology
13.2. Global Women’s Digital Health Market, 2023-2035
13.3. Distribution Across Key Market Segments
13.3.1. Women’s Digital Health Market: Distribution by Type of Solution, 2023 and 2035
13.3.1.1. Women’s Digital Health Market for Applications / Software, 2023-2035
13.3.1.2. Women’s Digital Health Market for Devices, 2023-2035
13.3.1.3. Women’s Digital Health Market for Services, 2023-2035
13.3.2. Women’s Digital Health Market: Distribution by Therapeutic Application Area, 2023 and 2035
13.3.2.1. Women’s Digital Health Market for Fetal Health, 2023-2035
13.3.2.2. Women’s Digital Health Market for General Wellness, 2023-2035
13.3.2.3. Women’s Digital Health Market for Menstrual Cycle, 2023-2035
13.3.2.4. Women’s Digital Health Market for Pelvic Care, 2023-2035
13.3.2.5. Women’s Digital Health Market for Reproductive Health / Fertility, 2023-2035
13.3.3. Women’s Digital Health Market: Distribution by Key Geographical Regions, 2023 and 2035
13.3.3.1. Women’s Digital Health Market in North America, 2023-2035
13.3.3.2. Women’s Digital Health Market in Europe, 2023-2035
13.3.3.3. Women’s Digital Health Market in Asia-Pacific, 2023-2035
13.3.3.4. Women’s Digital Health Market in Middle East and North Africa, 2023-2035
13.3.3.5. Women’s Digital Health Market in Latin America, 2023-2035
13.4. Women’s Digital Health Market for Applications / Software, 2023-2035
13.4.1. Women’s Digital Health Market for Applications / Software: Distribution by Therapeutic Application Area, 2023 and 2035
13.4.1.1. Women’s Digital Health Applications / Software Market for Fetal Health, 2023-2035
13.4.1.2. Women’s Digital Health Applications / Software Market for General Wellness, 2023-2035
13.4.1.3. Women’s Digital Health Applications / Software Market for Menstrual Cycle, 2023-2035
13.4.1.4. Women’s Digital Health Applications / Software Market for Pelvic Care, 2023-2035
13.4.1.5. Women’s Digital Health Applications / Software Market for Reproductive Health / Fertility, 2023-2035
13.4.2. Women’s Digital Health Market for Applications / Software: Distribution by Key Geographical Regions, 2023 and 2035
13.4.2.1. Women’s Digital Health Applications / Software Market in North America, 2023-2035
13.4.2.2. Women’s Digital Health Applications / Software Market in Europe, 2023-2035
13.4.2.3. Women’s Digital Health Applications / Software Market in Asia-Pacific, 2023-2035
13.4.2.4. Women’s Digital Health Applications / Software Market in Middle East and North Africa, 2023-2035
13.4.2.5. Women’s Digital Health Applications / Software Market in Latin America, 2023-2035
13.5. Women’s Digital Health Market for Devices, 2023-2035
13.5.1. Women’s Digital Health Market for Devices: Distribution by Therapeutic Application Area, 2023 and 2035
13.5.1.1. Women’s Digital Health Devices Market for Fetal Health, 2023-2035
13.5.1.2. Women’s Digital Health Devices Market for General Wellness, 2023-2035
13.5.1.3. Women’s Digital Health Devices Market for Menstrual Cycle, 2023-2035
13.5.1.4. Women’s Digital Health Devices Market for Pelvic Care, 2023-2035
13.5.1.5. Women’s Digital Health Devices Market for Reproductive Health / Fertility, 2023-2035
13.5.2. Women’s Digital Health Market for Devices: Distribution by Key Geographical Regions, 2023 and 2035
13.5.2.1. Women’s Digital Health Devices Market in North America, 2023-2035
13.5.2.2. Women’s Digital Health Devices Market in Europe, 2023-2035
13.5.2.3. Women’s Digital Health Devices Market in Asia-Pacific, 2023-2035
13.5.2.4. Women’s Digital Health Devices Market in Middle East and North Africa, 2023-2035
13.5.2.5. Women’s Digital Health Devices Market in Latin America, 2023-2035
13.6. Women’s Digital Health Market for Services, 2023-2035
13.6.1. Women’s Digital Health Market for Services: Distribution by Therapeutic Application Area, 2023 and 2035
13.6.1.1. Women’s Digital Health Services Market for Fetal Health, 2023-2035
13.6.1.2. Women’s Digital Health Services Market for General Wellness, 2023-2035
13.6.1.3. Women’s Digital Health Services Market for Menstrual Cycle, 2023-2035
13.6.1.4. Women’s Digital Health Services Market for Pelvic Care, 2023-2035
13.6.1.5. Women’s Digital Health Services Market for Reproductive Health / Fertility, 2023-2035
13.6.2. Women’s Digital Health Market for Services: Distribution by Key Geographical Regions, 2023 and 2035
13.6.2.1. Women’s Digital Health Services Market in North America, 2023-2035
13.6.2.2. Women’s Digital Health Services Market in Europe, 2023-2035
13.6.2.3. Women’s Digital Health Services Market in Asia-Pacific, 2023-2035
13.6.2.4. Women’s Digital Health Services Market in Middle East and North Africa, 2023-2035
13.6.2.5. Women’s Digital Health Services Market in Latin America, 2023-2035
Section V: Key Acquisition Targets, Business Risk Assessment and Return on Investments
14. KEY ACQUISITION TARGETS
14.1. Overview
14.2. Likely Acquisition Targets
15. BUSINESS RISK ASSESSMENT
15.1. Chapter Overview
15.2. Operations-related Risks
15.3. Business-related Risks
15.4. Financial / Asset-related Risks
15.5. Product / Technology Risks
15.6. Other Risks
16. RETURN ON INVESTMENTS
16.1. Overview and Methodology
16.2. Case Study
17. CONCLUSION
18. APPENDICES
List Of Figures
Figure 5.1. Women’s Digital Health: Benefits of Digital Health Technologies
Figure 5.2. Women’s Digital Health: Key Application Areas of FemTech Industry
Figure 5.3. Women’s Digital Health: Type of Product(s) / Solution(s) and Key Industry Players
Figure 5.4. Women’s Digital Health: Key Marketed Products and Challenges
Figure 5.5. Success Story: HeraMED
Figure 5.6. Success Story: Sera Prognostics
Figure 5.7. Business Decline Story: Bonzun
Figure 5.8. Business Decline Story: Braster
Figure 6.1. Innovator Landscape: Distribution by Year of Establishment
Figure 6.2. Innovator Landscape: Distribution by Type of Venture
Figure 6.3. Innovator Landscape: Distribution by Company Size
Figure 6.4. Innovator Landscape: Distribution by Type of Market
Figure 6.5. Innovator Landscape: Distribution by Number of Products
Figure 6.6. Innovator Landscape: Distribution by Geography
Figure 7.1. Product Landscape: Distribution by Current Status of Development
Figure 7.2. Product Landscape: Distribution by Type of Product(s) / Solution(s)
Figure 7.3. Product Landscape: Distribution by Regulatory Approval(s)
Figure 7.4. Product Landscape: Distribution by Therapeutic Application Area(s)
Figure 7.5. Product Landscape: Distribution by Usage Period wrt Pregnancy
Figure 7.6. Product Landscape: Distribution by Purpose(s)
Figure 7.7. Product Landscape: Distribution by End User(s)
Figure 8.1. Companies Offering Product-related Value: Distribution of Companies by Value Offered and Experience
Figure 8.2. Companies Offering Product-related Value: Distribution of Companies Offering Very High Value
Figure 8.3. Companies Offering Value to Patients: Distribution of Companies by Value Offered and Experience
Figure 8.4. Companies Offering Value to Patients: Distribution of Companies Offering Very High Value
Figure 8.5. Companies Offering Developer Value: Distribution of Companies by Value Offered and Experience
Figure 8.6. Companies Offering Developer Value: Distribution of Companies Offering Very High Value
Figure 8.7. Companies Offering Outreach-related Value: Distribution of Companies by Value Offered and Experience
Figure 8.8. Companies Offering Outreach-related Value: Distribution of Companies Offering Very High Value
Figure 8.9. Value Proposition Analysis: Concluding Remarks
Figure 9.1. Company Competitiveness Analysis: Large Companies based in North America (Peer Group I)
Figure 9.2. Company Competitiveness Analysis: Mid-sized Companies based in North America (Peer Group II)
Figure 9.3. Company Competitiveness Analysis: Small Companies based in North America (Peer Group III)
Figure 9.4. Company Competitiveness Analysis: Very Small Companies based in North America (Peer Group IV)
Figure 9.5. Company Competitiveness Analysis: Large and Mid-sized Companies based in Europe (Peer Group V)
Figure 9.6. Company Competitiveness Analysis: Small Companies based in Europe (Peer Group VI)
Figure 9.7. Company Competitiveness Analysis: Very Small Companies based in Europe (Peer Group VII)
Figure 9.8. Company Competitiveness Analysis: Large and Mid-sized Companies based in Asia-Pacific and Rest of the World (Peer Group VIII)
Figure 9.9. Company Competitiveness Analysis: Small Companies based in Asia-Pacific and Rest of the World (Peer Group IX)
Figure 9.10. Company Competitiveness Analysis: Very Small Companies based in Asia-Pacific and Rest of the World (Peer Group X)
Figure 10.1. Funding and Investment Analysis: Cumulative Year-wise Distribution of Funding Instances and Amount Invested, Pre-2013-2022 (USD Million)
Figure 10.2. Funding and Investment Analysis: Distribution of Instances by Type of Funding
Figure 10.3. Funding and Investment Analysis: Distribution of Instances by Type of Venture Capital Funding
Figure 10.4. Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
Figure 10.5. Funding and Investment Analysis: Distribution of Amount Invested by Venture Capital Funding (USD Million)
Figure 10.6. Funding and Investment Analysis: Geographical Distribution of Funding Instances
Figure 10.7. Funding and Investment Analysis: Geographical Distribution of Amount Invested (USD Million)
Figure 10.8. Funding and Investment Analysis: Most Active Players by Number of Instances
Figure 10.9. Funding and Investment Analysis: Most Active Players by Amount Raised (USD Million)
Figure 10.10. Funding and Investment Analysis: Most Active Investors by Number of Instances
Figure 10.11. Awards / Grants: Cumulative Instances and Amount Invested (USD Million)
Figure 10.12. Awards / Grants: Global Distribution of Amount Invested (USD Million)
Figure 10.13. Awards / Grants: Most Active Investors
Figure 10.14. Crowd Funding: Cumulative Instances and Amount Invested (USD Million)
Figure 10.15. Crowd Funding: Global Distribution of Amount Invested (USD Million)
Figure 10.16. Seed Funding: Cumulative Instances and Amount Invested (USD Million)
Figure 10.17. Seed Funding: Global Distribution of Amount Invested (USD Million)
Figure 10.18. Seed Funding: Most Active Investors
Figure 10.19. Venture (Series A): Cumulative Instances and Amount Invested (USD Million)
Figure 10.20. Venture (Series A): Global Distribution of Amount Invested (USD Million)
Figure 10.21. Venture (Series A): Most Active Investors
Figure 10.22. Venture (Series B): Cumulative Instances and Amount Invested (USD Million)
Figure 10.23. Venture (Series B): Global Distribution of Amount Invested (USD Million)
Figure 10.24. Venture (Series B): Most Active Investors
Figure 10.25. Venture (Series C): Cumulative Instances and Amount Invested (USD Million)
Figure 10.26. Venture (Series C): Global Distribution of Amount Invested (USD Million)
Figure 10.27. Venture (Series C): Most Active Investors
Figure 10.28. Venture (Series D): Cumulative Instances and Amount Invested (USD Million)
Figure 10.29. Venture (Series D): Global Distribution of Amount Invested (USD Million)
Figure 10.30. Venture (Series D): Most Active Investors
Figure 10.31. Venture (Series E): Cumulative Instances and Amount Invested (USD Million)
Figure 10.32. Venture (Series E): Global Distribution of Amount Invested (USD Million)
Figure 10.33. Venture (Series E): Most Active Investors
Figure 10.34. Public Offering: Cumulative Instances and Amount Invested (USD Million)
Figure 10.35. Public Offering: Global Distribution of Amount Invested (USD Million)
Figure 10.36. Private Placement: Cumulative Instances and Amount Invested (USD Million)
Figure 10.37. Private Placement: Global Distribution of Amount Invested (USD Million)
Figure 10.38. Private Placement: Most Active Investors
Figure 10.39. Debt Financing: Cumulative Instances and Amount Invested (USD Million)
Figure 10.40. Debt Financing: Global Distribution of Amount Invested (USD Million)
Figure 10.41. Debt Financing: Most Active Investors
Figure 10.42. Capital Investments in Women’s Digital Health: Summary of Investments, 2011-2022
Figure 11.1. Fundamental Financial Analysis: Annual Revenues and Key Balance Sheet Parameter-related Trends (Bonzun)
Figure 11.2. Fundamental Financial Analysis: Liquidity Ratios, 2-years Trend (Bonzun)
Figure 11.3. Fundamental Financial Analysis: Financial, Business Risk and Turnover / Efficiency Ratios, 2-years Trend (Bonzun)
Figure 11.4. Fundamental Financial Analysis: Profitability Ratios, 2-years Trend (Bonzun)
Figure 11.5. Fundamental Financial Analysis: Market Value and Stability Ratios, 2-years Trend (Bonzun)
Figure 11.6. Fundamental Financial Analysis: Annual Revenues and Key Balance Sheet Parameter-related Trends (HeraMED)
Figure 11.7. Fundamental Financial Analysis: Liquidity Ratios, 5-years Trend (HeraMED)
Figure 11.8. Fundamental Financial Analysis: Financial, Business Risk and Turnover / Efficiency Ratios, 5-years Trend (HeraMED)
Figure 11.9. Fundamental Financial Analysis: Profitability Ratios, 5-years Trend (HeraMED)
Figure 11.10. Fundamental Financial Analysis: Market Value and Stability Ratios, 5-years Trend (HeraMED)
Figure 11.11. Fundamental Financial Analysis: Annual Revenues and Key Balance Sheet Parameter-related Trends (Sera Prognostics)
Figure 11.12. Fundamental Financial Analysis: Liquidity Ratios, 3-years Trend (Sera Prognostics)
Figure 11.13. Fundamental Financial Analysis: Financial, Business Risk and Turnover / Efficiency Ratios, 3-years Trend (Sera Prognostics)
Figure 11.14. Fundamental Financial Analysis: Profitability Ratios, 3-years Trend (Sera Prognostics)
Figure 11.15. Fundamental Financial Analysis: Market Value and Stability Ratios, 3-years Trend (Sera Prognostics)
Figure 11.16. Technical Analysis: Stock Price (Candlestick Chart) and Volume Traded (Bonzun)
Figure 11.17. Technical Analysis: 5-Day Moving Average (Bonzun)
Figure 11.18. Technical Analysis: 10-Day Moving Average (Bonzun)
Figure 11.19. Technical Analysis: 50-Day Moving Average (Bonzun)
Figure 11.20. Technical Analysis: Bollinger Band® (Bonzun)
Figure 11.21. Technical Analysis: Relative Strength Index (Bonzun)
Figure 11.22. Technical Analysis: Williams’ R Analysis (Bonzun)
Figure 11.23. Technical Analysis: Moving Average Convergence Divergence (Bonzun)
Figure 11.24. Technical Analysis: Stock Price (Candlestick Chart) and Volume Traded (HeraMED)
Figure 11.25. Technical Analysis: 5-Day Moving Average (HeraMED)
Figure 11.26. Technical Analysis: 10-Day Moving Average (HeraMED)
Figure 11.27. Technical Analysis: 50-Day Moving Average (HeraMED)
Figure 11.28. Technical Analysis: Bollinger Band® (HeraMED)
Figure 11.29. Technical Analysis: Relative Strength Index (HeraMED)
Figure 11.30. Technical Analysis: Williams’ R Analysis (HeraMED)
Figure 11.31. Technical Analysis: Moving Average Convergence Divergence (HeraMED)
Figure 11.32. Technical Analysis: Stock Price (Candlestick Chart) and Volume Traded (Sera Prognostics)
Figure 11.33. Technical Analysis: 5-Day Moving Average (Sera Prognostics)
Figure 11.34. Technical Analysis: 10-Day Moving Average (Sera Prognostics)
Figure 11.35. Technical Analysis: 50-Day Moving Average (Sera Prognostics)
Figure 11.36. Technical Analysis: Bollinger Band® (Sera Prognostics)
Figure 11.37. Technical Analysis: Relative Strength Index (Sera Prognostics)
Figure 11.38. Technical Analysis: Williams’ R Analysis (Sera Prognostics)
Figure 11.39. Technical Analysis: Moving Average Convergence Divergence (Sera Prognostics)
Figure 12.1. Bonzun: Company Fundamentals
Figure 12.2. Bonzun: Company Technicals
Figure 12.3. HeraMED: Company Fundamentals
Figure 12.4. HeraMED: Company Technicals
Figure 12.5. Sera Prognostics: Company Fundamentals
Figure 12.6. Sera Prognostics: Company Technicals
Figure 13.1. Global Women’s Digital Health Market, 2023-2035 (USD Million)
Figure 13.2. Women’s Digital Health Market: Distribution by Type of Solution, 2023 and 2035
Figure 13.3. Women’s Digital Health Market for Applications / Software, 2023-2035 (USD Million)
Figure 13.4. Women’s Digital Health Market for Devices, 2023-2035 (USD Million)
Figure 13.5. Women’s Digital Health Market for Services, 2023-2035 (USD Million)
Figure 13.6. Women’s Digital Health Market: Distribution by Therapeutic Application Area, 2023 and 2035
Figure 13.7. Women’s Digital Health Market for Fetal Health, 2023-2035 (USD Million)
Figure 13.8. Women’s Digital Health Market for General Wellness, 2023-2035 (USD Million)
Figure 13.9. Women’s Digital Health Market for Menstrual Cycle, 2023-2035 (USD Million)
Figure 13.10. Women’s Digital Health Market for Pelvic Care, 2023-2035 (USD Million)
Figure 13.11. Women’s Digital Health Market for Reproductive Health / Fertility, 2023-2035 (USD Million)
Figure 13.12. Women’s Digital Health Market: Distribution by Key Geographical Regions, 2023 and 2035
Figure 13.13. Women’s Digital Health Market in North America, 2023-2035 (USD Million)
Figure 13.14. Women’s Digital Health Market in Europe, 2023-2035 (USD Million)
Figure 13.15. Women’s Digital Health Market in Asia-Pacific, 2023-2035 (USD Million)
Figure 13.16. Women’s Digital Health Market in Latin America, 2023-2035 (USD Million)
Figure 13.17. Women’s Digital Health Market in Middle East and North Africa, 2023-2035 (USD Million)
Figure 13.18. Women’s Digital Health Market for Applications / Software: Distribution by Therapeutic Application Area, 2023 and 2035
Figure 13.19. Women’s Digital Health Applications / Software Market for Fetal Health, 2023-2035 (USD Million)
Figure 13.20. Women’s Digital Health Applications / Software Market for General Wellness, 2023-2035 (USD Million)
Figure 13.21. Women’s Digital Health Applications / Software Market for Menstrual Cycle, 2023-2035 (USD Million)
Figure 13.22. Women’s Digital Health Applications / Software Market for Pelvic Care, 2023-2035 (USD Million)
Figure 13.23. Women’s Digital Health Applications / Software Market for Reproductive Health / Fertility, 2023-2035 (USD Million)
Figure 13.24. Women’s Digital Health Market for Applications / Software: Distribution by Key Geographical Regions, 2023 and 2035
Figure 13.25. Women’s Digital Health Applications / Software Market in North America, 2023-2035 (USD Million)
Figure 13.26. Women’s Digital Health Applications / Software Market in Europe, 2023-2035 (USD Million)
Figure 13.27. Women’s Digital Health Applications / Software Market in Asia-Pacific, 2023-2035 (USD Million)
Figure 13.28. Women’s Digital Health Applications / Software Market in Latin America, 2023-2035 (USD Million)
Figure 13.29. Women’s Digital Health Applications / Software Market in Middle East and North Africa, 2023-2035 (USD Million)
Figure 13.30. Women’s Digital Health Market for Devices: Distribution by Therapeutic Application Area, 2023 and 2035
Figure 13.31. Women’s Digital Health Devices Market for Fetal Health, 2023-2035 (USD Million)
Figure 13.32. Women’s Digital Health Devices Market for General Wellness, 2023-2035 (USD Million)
Figure 13.33. Women’s Digital Health Devices Market for Menstrual Cycle, 2023-2035 (USD Million)
Figure 13.34. Women’s Digital Health Devices Market for Pelvic Care, 2023-2035 (USD Million)
Figure 13.35. Women’s Digital Health Devices Market for Reproductive Health / Fertility, 2023-2035 (USD Million)
Figure 13.36. Women’s Digital Health Market for Devices: Distribution by Key Geographical Regions, 2023 and 2035
Figure 13.37. Women’s Digital Health Devices Market in North America, 2023-2035 (USD Million)
Figure 13.38. Women’s Digital Health Devices Market in Europe, 2023-2035 (USD Million)
Figure 13.39. Women’s Digital Health Devices Market in Asia-Pacific, 2023-2035 (USD Million)
Figure 13.40. Women’s Digital Health Devices Market in Latin America, 2023-2035 (USD Million)
Figure 13.41. Women’s Digital Health Devices Market in Middle East and North Africa, 2023-2035 (USD Million)
Figure 13.42. Women’s Digital Health Market for Services: Distribution by Therapeutic Application Area, 2023 and 2035
Figure 13.43. Women’s Digital Health Services Market for Fetal Health, 2023-2035 (USD Million)
Figure 13.44. Women’s Digital Health Services Market for General Wellness, 2023-2035 (USD Million)
Figure 13.45. Women’s Digital Health Services Market for Menstrual Cycle, 2023-2035 (USD Million)
Figure 13.46. Women’s Digital Health Services Market for Pelvic Care, 2023-2035 (USD Million)
Figure 13.47. Women’s Digital Health Services Market for Reproductive Health / Fertility, 2023-2035 (USD Million)
Figure 13.48. Women’s Digital Health Market for Services: Distribution by Key Geographical Regions, 2023 and 2035
Figure 13.49. Women’s Digital Health Services Market in North America, 2023-2035 (USD Million)
Figure 13.50. Women’s Digital Health Services Market in Europe, 2023-2035 (USD Million)
Figure 13.51. Women’s Digital Health Services Market in Asia-Pacific, 2023-2035 (USD Million)
Figure 13.52. Women’s Digital Health Services Market in Latin America, 2023-2035 (USD Million)
Figure 13.53. Women’s Digital Health Services Market in Middle East and North Africa, 2023-2035 (USD Million)
Figure 14.1. Key Acquisition Targets: Comparison of Scores with Overall Dataset
Figure 14.2. Key Acquisition Targets: Comparison based on Qualifying Parameters
Figure 15.1. Business Risk Analysis: Operations-related Risks
Figure 15.2. Business Risk Analysis: Business-related Risks
Figure 15.3. Business Risk Analysis: Financial / Asset-related Risks
Figure 15.4. Business Risk Analysis: Product / Technology Risks
Figure 15.5. Business Risk Analysis: Other Risks
Figure 16.1. Returns on Investment: Reported by Selected Stakeholders in Sera Prognostics and Historical Funding Activity
Figure 17.1. Concluding Landscape: North America
Figure 17.2. Concluding Landscape: Europe
Figure 17.3. Concluding Landscape: Asia-Pacific
List Of Tables
Table 6.1. List of Innovators in Women’s Digital Health Market
Table 7.1. List of Products: Information on Current Status of Development and Type of Product(s) / Solution(s)
Table 7.2. List of Products: Information on Regulatory Approval(s) and Therapeutic Application Area(s)
Table 7.3. List of Products: Information on Usage Period wrt Pregnancy, Purpose(s) and End User(s)
Table 7.4. Company Health Indexing: Scoring of Parameters
Table 7.5. Company Health Indexing: Leading Innovators
Table 8.1. Value Proposition Analysis: Key Values and Scores
Table 9.1. Company Competitiveness Analysis: Scoring of Parameters
Table 12.1. Bonzun: Insights from Balance Sheet
Table 12.2. HeraMED: Insights from Balance Sheet
Table 12.3. Sera Prognostics: Insights from Balance Sheet
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- #ANGELS
- 14W
- 15th Rock
- 1776 Ventures
- 1984 Ventures
- 2048 Ventures
- 3L
- 415 Ventures
- 4FO Ventures
- 500 Global
- 500 Startups
- 8VC
- 9Unicorns
- a thousand colibris
- AH trust
- Aavia
- Accorded
- ACME Capital
- Act One Ventures
- Activision Blizzard
- Acumen
- Ad Astra Ventures
- Adaptive Health Capital
- Aindra Systems
- Alife
- Alkemi Growth capital
- Allara
- AllBright
- AlleyCorp
- Alpha Femtech
- Alsace Business Angels
- Althea
- Altimeter Capital Management
- Altitude Ventures
- Alumni Ventures
- Amboy Street Ventures
- America's Seed Fund
- aMoon
- Amplo
- Anchorless Bangladesh
- Andera Partners
- Andreessen Horowitz
- Angeles Investment Advisors
- AngelList
- Ankur Capital
- Anthem
- AOA Dx
- AoI Ventures
- App Basic
- Apricity
- Arbor
- Arboretum Ventures
- ArlanWasHere Investments
- Artesian
- Ascension Ventures
- Aspivix
- Asset Management Ventures
- Astia Angels
- Astinno
- ATH Holding Company
- Atlantic Bridge
- Atlantic Health System
- Atlantic Therapeutics
- AtlasV
- Atomico
- Atreyu
- Aurora Health Care
- Ava
- Avaana Capital
- Avestria Ventures
- Awesome People Ventures
- aws Gründerfonds
- Axilor
- Baby2Body
- Babyscripts
- Backstage Capital
- Baker Bros. Advisors
- balance
- Balderton
- Band of Angels
- Banner Health
- BBG Ventures
- Beacon Angels
- BEENEXT
- Begin Capital
- Bellabeat
- Bethnal Green Ventures
- BGF
- Bia Med
- Bill & Melinda Gates Foundation
- Biowink
- Black Capital
- Black Pearl Global Investments
- Blackbird
- BlackRock
- Bloody Health
- Bloomer Tech
- Bloomlife
- Bloomth
- Blossom Capital
- Blue Cross Blue Shield of Massachusetts
- Blue Ocean Ventures
- Blue Ox Healthcare Partners
- BlueRun Ventures
- Blume Equity
- BNP Paribas
- Bolt Ventures
- BOND
- Bonnier Ventures
- Bonzun
- Borski Fund
- Bose Ventures
- BoxGroup
- Bramalea Partners
- Bread and Butter Ventures
- breathe ilo
- BrightCap Ventures
- Brilliantly
- Broadway Angels
- btov
- Business Angels Club Berlin-Brandenburg
- Business Angels Switzerland
- B-wom
- Cambia Health Solutions
- Cambridge Digital Health
- Canaan
- Candlelit
- Canopie
- Capier Investments
- Capital Angel Network
- Care4Cute
- CareSignal
- Carnrite Ventures
- Carrot Fertility
- Casdin Capital
- Catalyst Health Ventures
- Cayaba Care
- CG Health Ventures
- Chemo
- Cherubic Ventures
- Chiaroscuro Foundation
- Chione
- Chiratae Ventures
- Chorus Health
- Chrysalis
- Cigna Ventures
- Claritas Capital
- Clementine
- CM-CIC Innovation
- Coelius Capital
- Collaborative Fund
- Colle Capital
- Combine
- Commonfund
- Company Ventures
- Compound
- Connect
- Connecticut Innovations
- Core Innovation Capital
- Cormorant Asset Management
- Coroflo
- Correlation Ventures
- Cortado Ventures
- Crescent Ridge
- CrunchFund
- CRV
- CU Healthcare Innovation Fund
- Deerfield
- Define Ventures
- Development Bank of Wales
- Digitalis Ventures
- DigiTx Partners
- DilenyTech
- Domain Associates
- Downing Ventures
- Dragoneer Investment Group
- Draper Associates
- Dream Incubator
- DSM Venturing
- Earlybird Venture Capital
- Ease Healthcare
- Easton Capital Investment Group
- Echo Health Ventures
- EIT Health
- ElaWoman
- Elda Health
- Eldridge
- Eli Health
- Elidah
- EloCare
- e-L?vu Health
- Elvie
- Elysium Venture Capital
- Embr Labs
- Embria
- Emme (a part of SimpleHealth)
- Endeavour Vision
- Endodiag
- Endometrix
- ENSE Group
- Enterprise Ireland
- Enzia Ventures
- Episcopal Health Foundation
- EQT Ventures
- eQventure
- Established Ventures
- European Commission
- European Innovation Council and SMEs Executive Agency (EISMEA)
- Evernow
- Exandus
- Exor
- F Cubed
- Felix Capital
- Female Founders Fund
- Femcare Fertility
- Femcy
- FemHealth Ventures
- FEMM
- Femna Health
- Femometer
- FemTech Healthcare
- FemX
- fermata
- Ferne Health
- FetoLife
- Firestartr
- First Round Capital
- FirstCheck Africa
- FirstMark
- Fizimed
- Flanders Innovation and Entrepreneurship (VLAIO)
- Flare Capital Partners
- Flint Capital
- Flo Health
- Flo Living
- Flöka
- Foothill Ventures
- Forerunner
- Formation 8
- Fors Marsh
- Fortunis Capital
- Foundation for Technological Innovation
- Founders Fund
- Foview
- F-Prime
- Frame Fertility
- Freemark Financial
- Froedtert & the Medical College of Wisconsin
- Frøya Life
- Fuel Ventures
- Future Positive Capital
- Future\Perfect Ventures
- Gaingels
- Gals Bio
- gBETA Medtech
- General Catalyst
- General Electric
- Gennev
- GingerBread Capital
- Giving Wings
- Global Founders Capital
- Global Sources
- Glow
- Golden Seeds
- Goldman Sachs
- Goodgrower
- Google Ventures
- Gopher Asset Management
- Grand Central Tech
- Great Oaks Venture Capital
- Green D Ventures
- Greycroft
- Groupe Arnault
- GSK
- Hackster
- Halza
- Hambrecht Ducera Growth Ventures
- Harmony Partners
- Hatteras Venture Partners
- Haxus
- Headline
- Health & Her
- Health Enterprise Partners
- Health in Her Hue
- HealthTech Capital
- HeraMED
- Hikma Ventures
- Hiro Capital
- Hiventures
- HLM Venture Partners
- Homebrew
- Horizon 2020
- Houston Angel Network (HAN)
- Hoxton Ventures
- Hubble Connected
- Human Ventures
- Humbition
- Hustle Fund
- HVF
- IA Ventures
- IBB Capital
- iBreve
- Icon Ventures
- Illumigyn
- Illumina Ventures
- iMama
- Impact Ventures
- Index Ventures
- Information Technology Academia Collaboration (ITAC)
- Initialized Capital
- Inito
- inne
- InnovaHealth Partners
- Innovate UK
- Inova
- Insignia Ventures Partners
- Inspired Capital
- InterWest Partners
- Invest Ottawa
- IPGL
- iSeed Capital
- iSono Health
- Iterative
- iXensor
- January Ventures
- Jennis
- Johnson & Johnson Innovation
- Joyance Partners
- JumpStart
- Kamet Ventures
- Kapor Capital
- kegg
- Kensington Capital Partners
- Kheiron Medical Technologies
- Khyria
- Kimera
- Kindbody
- KMG Partners
- KOFA Healthcare
- Konna
- KYTO Technology & Life Science
- Labcorp
- LabQ International
- Lactamo
- LactApp
- Lactation Lab
- Laerdal Medical
- Laia
- Lanza techVentures
- LaunchCapital
- Launchpad Venture Group
- Leap Fitness Group
- Leerink Transformation Partners
- Lemonaid Health
- LetsGetChecked
- LifeSense Group (LSG)
- Lightbank
- Lightship Capital
- Lightstone Ventures
- Linchpin Technologies
- LionBird
- Lisa Health
- Livia
- Logos Capital
- LOI Venture
- Lone Pine Capital
- Longmeadow Capital Partners
- Longwood Fund
- Looking Glass Capital
- Lovetap
- Lucina Analytics
- Luminary Labs
- Lux Capital
- Mabel
- Mae
- MagicGirl
- Magnetic Ventures
- Mahmee
- Maki.vc
- Mangrove Capital Partners
- MassChallenge
- Material Impact
- Materna Medical
- Maven Clinic
- Maveron
- Maya Digital Health
- Mayo Clinic
- MBX Capital
- MegaForce
- MEMEDA
- MemorialCare Innovation Fund
- Menopod
- Merchavia Holdings and Investments
- Meridian Street Capital
- Meritech
- Metrodora Ventures
- Metronomic Health
- MiMARK
- Mira
- MobileODT
- Monashee Investment Management
- Monkfish Equity
- Monk's Hill Ventures
- MooDoos Investments
- Moonai
- Mordern Fertility (a subsidiary of Ro)
- Mosaic Ventures
- Muse Capital
- MUTU
- MyAva
- Nabta Health
- National Cancer Institute (NCI)
- National Institutes of Health
- National Science Foundation (NSF)
- Natural Cycles
- Naytal
- NC IDEA
- NEA
- Nest Collaborative
- NextCell Pharma
- Nexus Venture Partners
- NFP
- NGP Capital
- Niramai
- Novartis Venture Fund
- NueCura Partners
- Nueterra Capital
- NursElet
- Nuvo
- Oak HC/FT
- Oath Care
- OCON Healthcare
- Octopus Ventures
- Olive Tree Ventures
- OMERS Ventures
- One Brave Idea
- Oova
- Optum Ventures
- OrbiMed
- Ordinary Folk
- Orios Venture Partners
- Orreco
- Osage University Partners
- OSF Ventures
- Oula
- Ovia Health
- Ovira
- Ovulai
- Ovulation Calculator
- P5 Health Ventures
- Pachamama
- Parentlane
- Parian Global Management
- Partech
- PBJ Capital
- Peanut
- Pepapp
- Perceptive Advisors
- Perigee
- Philips
- pi Ventures
- Pioneer Fund
- Pipeline Angels
- Plackal
- Plug and Play
- Polytech Ventures
- Pomelo Care
- Pontifax
- Portfolia
- Precursor Ventures
- PregnaScan
- Prima-Temp
- Prime Venture Partners
- Proactive for her
- Promus Ventures
- Proov
- Providence Ventures
- pumpspotting
- Punchbowl
- Pura Vida
- Purple Arch Ventures
- Qiming Venture Partners
- Radical Ventures
- Raiing Medical
- Raydiant Oximetry
- Refactor Capital
- Renalis
- Renovia
- Revolution
- Rhia Ventures
- Ro
- Rock Health
- Rock Springs Capital
- ROHTO Pharmaceutical
- RRE Ventures
- Safar Partners
- Santora Nakama
- SDVentures
- Seae Ventures
- Seashore Solutions
- Sequoia
- Sera Prognostics
- Seroba Life Sciences
- Seven Seven Six
- Sevenlogics
- Shareholder Value Management
- Shatter Fund
- ShawSpring Partners
- She Raises Capital
- Sherpa Ventures
- SideCar Angels
- SignalFire
- Silicon Valley Bank
- Sinai Ventures
- Slow Ventures
- Social Starts
- Softtech Ventures
- Sonrava Health
- SOSV
- Sound Ventures
- Special Situations Life Sciences Innovation Fund
- Spring Mountain Capital
- Springbank Collective
- SRI International
- Srirakshaa Healthcare
- St. George Bank
- Starting Line
- Start-Up Chile
- StartUp Health
- Startup Karnataka
- SteadySense
- SteelSky Ventures
- Storka
- Sunstone Partners
- SV Angel
- SVC
- Sweet Capital
- Swisscom Ventures
- Syrona Health
- Tamtris Web Services
- Tara Health Foundation
- Target Global
- TBD Angels
- Techammer
- Techstars
- Tempdrop
- Teneo
- Texas HALO Fund
- Texas Medical Center Innovation
- The Baupost Group
- The Body Literacy Collective
- The Chernin Group
- The Female Health Hub
- The Handler
- The Helm
- The Kresge Foundation
- The Lily Project
- The Osiris Group
- The Pelvic Expert
- The Sputnik Group
- Think Bigger Capital
- Third Culture Capital (3CC)
- Threshold Ventures
- Tia
- Tiger Global Management
- Titan Capital
- TMV
- Together For Her
- Torch Capital
- TQ Ventures
- Transformation Capital
- Trimble Ventures
- Tristel
- TruDiary
- True Ventures
- TT Capital Partners
- Tusk Venture Partners
- U.S. Venture Partners
- Ubicom (acquired by Qualcomm)
- Uncork Capital
- Union Square Ventures
- UnityPoint Health Ventures
- Universal Music Group
- University Hospitals
- UpStart VC
- Uvi Health
- Vcapital
- Vectr
- Veera Health
- Vega Ventures
- Velmio
- Venrex
- Venture Kick
- Vertex Ventures Southeast Asia and India
- Victorum Capital
- Viento Capital
- Villgro
- Virginia Venture Partners
- Vivant
- Vivo Capital
- VNV Global
- Wachanga
- Walking Ventures
- Watkins-Conti Products
- Wavemaker Three-Sixty Health
- WCC Partners
- Westerly Winds
- Western Development Commission
- Western Technology Investment
- Wildflower Health
- Willow
- Winklevoss Capital
- Women's Venture Fund
- WOMENUP
- WOOM (a subsidiary of Apricity)
- XA Network
- XYZ Venture Capital
- Y Combinator
- Yesmom
- Yozma
- Ysios Capital
- Zaya Care
- Zero Mothers Die
- Zoie Health
- Zu?rcher Kantonalba
Methodology
LOADING...
